Aquestive Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Chief People Officer Peter Boyd adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the “Boyd Plan”) on September 2, 2026. The Boyd Plan will commence on December 1, 2026 and ends on November 30, 2027. The maximum number of shares to be sold under the Boyd Plan is 200,000 shares, and no shares have been sold as of the date of this Report; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Boyd Plan.
Director Julie Krop adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the “Krop Plan”) on September 15, 2026. The Krop Plan will commence on December 14, 2026 and will end on June 30, 2027. The maximum number of shares to be sold under the Krop Plan is 105,000 shares, and no shares have been sold as of the date of this Report; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Krop Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.